Business Wire

Wyss Center Geneva Appoints Erwin Böttinger as new Chief Executive Officer

3.4.2023 10:14:00 CEST | Business Wire | Press Release

Share

The Executive Board of the Wyss Center for Bio and Neuroengineering, a non-profit research center, is pleased to announce the appointment of Prof. Dr. med. Erwin Böttinger as its new Chief Executive Officer (CEO).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230331005252/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Prof. Dr. med. Erwin Böttinger, Chief Executive Officer of the Wyss Center for Bio and Neuroengineering. Credit: Wyss Center

The appointment follows a funding commitment of CHF 120 million from the Wyss Foundation to further strengthen the Center’s mission to accelerate innovative therapies to the clinic to transform the lives of people with brain disorders.

Professor Steven E. Hyman, MD, Director, Stanley Center for Psychiatric Research at the Broad Institute and Co-Chair of the Wyss Center Executive Board: “Erwin is a pioneer in life science research and a visionary and experienced leader in translating promising technologies to improve patient care. Since its founding, the Wyss Center has developed strong systems to advance vital technologies to the clinic. Erwin’s appointment will accelerate these translational efforts so that I look forward to seeing new diagnostics and therapies that will transform many lives in the years to come.”

Prof. Erwin Böttinger: “I am proud and privileged to lead the Wyss Center and to focus on making a real difference to the lives of people with neurological and mental health disorders.

“We have a bold plan to innovate and accelerate transformational technologies in artificial intelligence, bio- and neuroengineering to restore essential neural functions or reset abnormal neural circuits in people with devastating brain disorders. Together with our partners from the École Polytechnique Fédérale de Lausanne, the University of Geneva and Geneva University Hospital, the Wyss Center is poised to catalyze the unique concentration of world-class brain health research at Campus Biotech to drive clinical breakthroughs.”

Campus Biotech is a neuroscience and innovation center of excellence in Geneva, Switzerland, that provides a collaborative environment in advanced research facilities, as well as space for start-ups and industrial partnerships.

Prof. Böttinger has a longstanding track record in personalized medicine, with emphasis on genomics and digital technologies. Before joining the Wyss Center, he was instrumental in building the Charles Bronfman Institute for Personalized Medicine and the Hasso Plattner Institute for Digital Health at Mount Sinai, at the Icahn School of Medicine at Mount Sinai in New York City, both with a strong translational focus. He also served as founding director of the Digital Health Center at the Hasso Plattner Institute for Digital Engineering and University Potsdam, and as CEO of the Berlin Institute of Health, Berlin, Germany.

Prof. Böttinger replaces Dr. Mary Tolikas who stepped down as CEO in 2022.

ENDS

Download high resolution images

About the Wyss Center for Bio and Neuroengineering

The Wyss Center is an independent, non-profit, research organization that accelerates innovative therapies to transform the lives of people with brain disorders.

The Center pursues transformational technologies in artificial intelligence, bio- and neuroengineering to restore essential neural functions and deliver precision therapeutics for people with debilitating neurological and mental health disorders.

Based at Campus Biotech in Geneva, Switzerland, the Wyss Center partners with faculty, clinicians and industry, in Switzerland and internationally, to drive innovation and maximize clinical impact.

The Wyss Center was established by a generous donation from the Swiss entrepreneur and philanthropist Hansjörg Wyss in 2014. Additional resources from funding agencies and other sources help the Wyss Center achieve its mission.

www.wysscenter.ch/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Wyss Center media contact

Jo Bowler, Communications Manager
+41 (0) 58 201 03 09
johanna.bowler@wysscenter.ch

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press Release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye